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Exposure to ionizing radiation (IR) increases the production of reactive oxygen species (ROS) not only by
the radiolysis of water but also through IR-induced perturbation of the cellular metabolism and dis-
turbance of the balance of reduction/oxidation reactions. Our recent studies showed that the increased
production of intracellular ROS induced by IR contributes to IR-induced late effects, particularly in the
hematopoietic system, because inhibition of ROS production with an antioxidant after IR exposure can
mitigate IR-induced long-term bone marrow (BM) injury. Metformin is a widely used drug for the
treatment of type 2 diabetes. Metformin also has the ability to regulate cellular metabolism and ROS
production by activating AMP-activated protein kinase. Therefore, we examined whether metformin can
ameliorate IR-induced long-term BM injury in a total-body irradiation (TBI) mouse model. Our results
showed that the administration of metformin signiﬁcantly attenuated TBI-induced increases in ROS
production and DNA damage and upregulation of NADPH oxidase 4 expression in BM hematopoietic
stem cells (HSCs). These changes were associated with a signiﬁcant increase in BM HSC frequency, a
considerable improvement in in vitro and in vivo HSC function, and complete inhibition of upregulation
of p16Ink4a in HSCs after TBI. These ﬁndings demonstrate that metformin can attenuate TBI-induced long-
term BM injury at least in part by inhibiting the induction of chronic oxidative stress in HSCs and HSC
senescence. Therefore, metformin has the potential to be used as a novel radioprotectant to ameliorate
TBI-induced long-term BM injury.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Bone marrow (BM) suppression is the most common side effect
of conventional cancer therapy using ionizing radiation (IR) and
chemotherapeutic agents and is the primary cause of death after
accidental or intentional exposure to high doses of total-body ir-
radiation (TBI) [1–4]. Acute myelosuppression is the result of the
induction of apoptosis in the rapidly proliferating hematopoietic
progenitor cells (HPCs) and to a lesser degree in the relatively
quiescent hematopoietic stem cells (HSCs) after exposure to IR and
chemotherapy [2,3]. Acute BM suppression can cause high mor-
tality and morbidity but has been better managed by the use of
various hematopoietic growth factors (HGFs), which have theInc. This is an open access article u
@uams.edu (D. Zhou), ai_min_menability to promote the recovery of BM hematopoietic function
primarily by stimulating HSC and HPC proliferation and differ-
entiation [4,5]. Although many patients recover rapidly from acute
myelosuppression after IR and/or chemotherapy, a large percen-
tage of the patients will develop residual BM injury manifested by
a decrease in HSC reserves and impairment in HSC self-renewal
[1,2]. Unlike acute myelosuppression, residual BM damage is la-
tent. Patients and animals with residual BM injury usually have
normal blood cell counts under normal homeostatic conditions
despite a decrease in HSC reserves [4,5]. Because of this latency,
the clinical implications of residual BM injury have been largelynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
g@126.com (A. Meng).
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further obscured by the seemingly complete recovery of peripheral
blood cell counts and BM cellularity, especially after the use of
HGFs. In fact, the use of HGFs may worsen chemotherapy- and IR-
induced residual BM damage by promoting HSC and HPC pro-
liferation and differentiation at the expense of HSC self-renewal
[6–8]. This could lead to an accelerated exhaustion of HSCs and
further compromise the long-term recovery of BM hematopoietic
function. Although residual BM damage is latent, it is long-lasting
and shows a slight tendency for recovery [1]. Therefore, an effec-
tive treatment that can prevent and/or mitigate irradiation-in-
duced long-term BM suppression is needed.
Evidence has emerged that IR induces residual BM injury pri-
marily via the induction of HSC senescence [4,5], which is an ir-
reversible loss of the proliferation capacity of HSCs. Our recent
studies have demonstrated that exposure of mice to a sublethal
dose of TBI induces persistent oxidative stress in HSCs in part via
the upregulation of NADPH oxidase 4 (NOX4) [9]. Oxidative stress
can induce HSC senescence by causing sustained DNA damage
and/or inducing p16Ink4a (p16) expression through the p38 mito-
gen-activated protein kinase pathway [10–14]. Several recent
studies have shown that the induction of oxidative stress is pri-
marily responsible for the loss of HSC self-renewal and premature
exhaustion of HSCs in mice with mutation of ataxia telangiectasia
[11,15] and deletion of FoxO3(s) [12–14]. Furthermore, prolonged
treatment of these mice with an antioxidant can rescue the defect
[11–15].
Metformin (1,1-dimethylbiguanide hydrochloride), a biguanide
derivate, is the most widely prescribed drug for the treatment of
hyperglycemia in individuals with type 2 diabetes. It also has the
ability to regulate cellular metabolism and reactive oxygen species
(ROS) production by the activation of AMP-activated protein ki-
nase (AMPK) [16–18]. Apart from its well-known antidiabetic ef-
fect, metformin also has antiaging [19–21] and anticancer activ-
ities [22–26]. Emerging evidence from epidemiological studies
suggests that diabetic patients treated with metformin have a
lower risk of cancer incidence and mortality in a broad range of
neoplasms [27,28]. Its antioxidant effect may be one of the im-
portant molecular mechanisms of action of metformin because
metformin can directly scavenge ROS or act indirectly to modulate
intracellular production of superoxide anion, of which NOXs con-
stitute a major source [29]. Additionally, metformin can increase
the expression of the antioxidant thioredoxin, which mediates
metformin’s effects on ROS reduction. Metformin increases thior-
edoxin expression through activation of the AMPK pathway [30].
Moreover, metformin can protect tissues or cells against DNA da-
mage and mutations by inhibiting the formation of ROS [31–37]. In
recent years, studies have found that metformin possesses radio-
protective properties against radiation-induced tissue or cell da-
mages in cochlear and splenic cells [38,39]. Because of the re-
markable therapeutic potential of metformin, we examined its
effects on TBI-induced long-term BM suppression in our well-es-
tablished and characterized mouse model. The data presented in
this study demonstrate that metformin treatment signiﬁcantly
inhibited the TBI-induced increases in the levels of ROS, DNA
double-strand breaks (DSBs), and NOX4 expression in HSCs. The
reduction in oxidative stress was associated with signiﬁcant in-
creases in HSC frequency and clonogenic function. These ﬁndings
suggest that metformin treatment may inhibit IR-induced HSC
senescence. This suggestion is supported by the ﬁnding that
metformin treatment reduced the IR-induced expression of p16
mRNA in HSCs and improved the long-term and multilineage en-
graftment of irradiated HSCs after transplantation. Therefore, the
results from this study demonstrated that metformin has the po-
tential to be used as a novel radioprotectant to ameliorate TBI-
induced residual BM injury.Materials and methods
Reagents
Anti-mouse CD117 (c-kit)-APC (clone 2B8), anti-mouse Ly-6 A/
EA (Sca-1)-PE/Cy7 (clone D7), biotin-conjugated anti-mouse CD5
(clone 53-7.3), biotin-conjugated anti-mouse CD4 (clone GK1.5),
anti-mouse CD8 (clone 53-6.7), anti-mouse CD45R/B220 (clone
RA3-6B2), anti-mouse Ly6G/Gr-1 (clone RB6-8C5), anti-mouse
CD11b (clone M1/70), anti-mouse Ter-119 (clone Ter-119), and
APC-Cy7-conjugated streptavidin were obtained from eBioscience
(San Diego, CA, USA). Anti-mouse CD45.1-FITC (clone A20, Ly5.1),
anti-mouse CD45.2-PE (clone104, Ly5.2), anti-mouse Ly6G/Gr-1-
PE/Cy7 (cloneRB6-8C5), anti-mouse CD45R/B220-PerCP (clo-
neRA3-6B2), anti-mouse CD11b-PE/Cy7 (cloneM1/70), anti-mouse
CD3-APC (clone145-2C11), and streptavidin-PerCP (405213) were
obtained from Biolegend (San Diego, CA, USA). 2′,7′-Di-
chlorodihydroﬂuorescein diacetate (DCFDA) and dichloro-
ﬂuorescein (DCF) were obtained from Sigma (St. Louis, MO, USA).
Dihydroethidium (DHE) was obtained from Vigorous (Beijing,
China). MitoSOX red mitochondrial superoxide indicator was ob-
tained from Life Technologies (Grand Island, NY, USA). Rabbit anti-
γH2AX was obtained from Cell Signaling Technology (Danvers,
MA, USA). Rabbit anti-NOX4 was obtained from Proteintech
(Wuhan, China). FITC-conjugated goat anti-rabbit antibodies were
obtained from Abcam Biotechnology (Cambridge, MA, USA). Cy-
toﬁx/Cytoperm buffer (554722), Perm/Wash buffer (554723), and
Cytoperm Permeabilization Buffer Plus (561651) were obtained
from BD Pharmingen (San Diego, CA, USA). Metformin was ob-
tained from Beyotime Institute of Biotechnology (CAS No. 1115-70-
4; Shanghai, China).
Mice
Male C57BL/6-Ly-5.1 (Ly5.1) and C57BL/6-Ly-5.2 (Ly5.2) mice
were purchased from Vital River (Beijing, China) and housed in the
certiﬁed animal facility at the Institute of Radiation Medicine of
the Chinese Academy of Medical Sciences (CAMS). C57BL/6-Ly-5.1/
5.2 (Ly5.1/5.2) mice were bred at the certiﬁed animal care facility
at the Institute of Radiation Medicine of CAMC. All of the mice
were used at approximately 8–12 weeks of age. All of the ex-
perimental procedures were performed with the approval of the
Animal Use Committee at the Institute of Radiation Medicine of
CAMS (No. 1202).
TBI and metformin administration
Ly5.2 mice were divided randomly into three groups:
(a) control, (b) vehicleþTBI, and (c) metforminþTBI. The mice in
the metforminþTBI group were administered a dose of 250 mg/
kg/day metformin by gavage 1 day before irradiation and 7 days
after irradiation. As the control, the mice in the vehicleþTBI group
received the same volume of distilled water at the same frequency
and duration as the mice in the metforminþTBI group. The mice
in the vehicleþTBI and metforminþTBI groups were exposed to
4.0- Gy TBI in an Exposure Instrument Gammacell-40 137Cs irra-
diator (Atomic Energy of Canada Ltd, Ottawa, ON, Canada) at a
dose rate of 0.78 Gy/min. The control mice were sham-irradiated.
Isolation of BM mononuclear cells (BM-MNCs) and HSCs
BM-MNCs were isolated from BMNCs as described previously
[4,5]. They were incubated with biotin-conjugated antibodies
speciﬁc for murine CD5, CD11b, CD45R/B220, Ter-119, and Gr-1
and then stained with streptavidin-APC-Cy7, anti-Sca-1-PE/Cy7,
and anti-c-kit-APC. HSCs (Linc-kitþSca-1þ) were analyzed and
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CA, USA).
Cobblestone area-forming cell (CAFC) assay
The CAFC assay was performed as described elsewhere [4,5].
Competitive repopulation assay
Competitive repopulation assays were performed using the Ly5
congenic mice as described previously [9,40]. Speciﬁcally, donor
BM cells (BMCs) were harvested from C57BL/6-Ly-5.2 mice after
the various treatments. The cells (1  106 BMCs) were mixed with
2  105 competitive BMCs pooled from six Ly5.1 mice. The mixed
cells were transplanted into lethally irradiated (9.0- Gy TBI) C57BL/
6-Ly-5.1/5.2 hybrid recipient mice (nine mice/group) by lateral
canthus vein injection. For analysis of engraftment, peripheral
blood was obtained from the medial canthus using heparin-coated
micropipettes (Drummond Scientiﬁc, Broomall, PA, USA) from all
of the recipients 4 months after transplantation. After the red
blood cells were lysed with 0.15 mol/L NH4Cl solution, the blood
samples were stained with FITC-conjugated anti-CD45.1, PE-con-
jugated anti-CD45.2, PerCP-conjugated anti-B220, APC-conjugated
anti-CD3, and PE/Cy7-conjugated anti-Gr-1 and CD11b and were
analyzed using an LSR II ﬂow cytometer (BD Bioscience).
Analysis of the levels of intracellular ROS
BM-MNCs were isolated from BMNCs as described previously
[4,5]. They were incubated with biotin-conjugated antibodies
speciﬁc for murine CD5, CD11b, CD45R/B220, Ter-119, and Gr-1
and then stained with streptavidin-APC-Cy7, anti-Sca-1-PE/Cy7,
and anti-c-kit-APC. Then the cells were incubated with DCF
(10 μM), DCFDA (10 μM), DHE (10 μM), and MitoSOX (5.0 μM),
respectively, for 20 min at 37 °C. The levels of intracellular ROS in
HSCs were analyzed by measuring the mean ﬂuorescence intensity
(MFI) of DCF, ethidium, and oxidized MitoSOX using a ﬂow cyto-
meter as described previously. The speciﬁcity of this assay to de-
tect intracellular ROS in HSCs was validated in our recently re-
ported studies [9,40]. For each sample, a minimum of 100,000
Lin cells were acquired, and the data were analyzed using the
FlowJo 7.6.1 software (Tree Star, Ashland, OR, USA). In all of the
experiments, PE/Cy7 and APC isotype controls and other positive
and negative controls were included as appropriate.
Analysis of γH2AX staining and NOX4 expression in HSCs
BM-MNCs were isolated from BMNCs as described previously
[4,5]. They were incubated with biotin-conjugated antibodies
speciﬁc for murine CD4, CD8, CD11b, CD45R/B220, Ter-119, and Gr-
1 and then stained with streptavidin-PerCP, anti-Sca-1-PE/Cy7, and
anti-c-kit-APC. The cells were ﬁxed and permeabilized by BD Cy-
toﬁx/Cytoperm buffer according to the manufacturer’s protocol
and then stained with antibodies against γH2AX or NOX4 and
FITC-conjugated second antibodies. γH2AX and NOX4 expression
in HSCs was determined by analysis of the MFI of γH2AX and
NOX4 staining in HSCs by ﬂow cytometry.
Quantitative real-time PCR assays
Total RNA from 5000 sorted HSCs was extracted using the
TRIzol reagent (Life Technologies) following the manufacturer’s
protocol. The expression of p16, NOX4, superoxide dismutase 1
(SOD1), SOD2, catalase (CAT), and glutathione peroxidase 1 (GPX1)
mRNAwas determined by real-time RT-PCR as previously reported
[41].Apoptosis assay
The apoptosis assay was performed as we previously reported
[3,5].
Analysis of enzymatic activity of SOD, CAT, and GPX1
SOD, CAT, and GPX1 enzymatic activities in BM-MNCs were
analyzed using SOD, CAT, and GPX1 assay kits (Beyotime Institute
of Biotechnology), respectively. The assays were done by following
the manufacturer’s instructions.
Statistical analysis
The data were analyzed by analysis of variance. Differences
were considered signiﬁcant at po0.05. All of these analyses were
performed using GraphPad Prism from GraphPad Software (San
Diego, CA, USA).Results
Metformin inhibits TBI-induced chronic oxidative stress in HSCs
In our previous studies, we have demonstrated that the ex-
posure of mice to a sublethal dose of TBI causes long-term BM
suppression in part by induction of chronic oxidative stress and
HSC senescence [9,40,41]. Metformin has the ability to reduce
oxidative tissue damage via several different mechanisms in var-
ious pathological conditions [29]. Therefore, we examined whe-
ther metformin can ameliorate TBI-induced long-term BM sup-
pression via inhibition of ROS production. ROS production in HSCs
4 weeks after TBI was analyzed initially by ﬂow cytometry after
DCFDA staining. As shown in Figs. 1A and 1B, the production of
ROS in HSCs was signiﬁcantly elevated after TBI according to the
analysis of DCF MFI after the cells were incubated with DCFDA. The
increases in DCF MFI in irradiated HSCs are unlikely to be attri-
butable to the changes in the probe ester cleavage, uptake, or ef-
ﬂux, because HSCs from both control and irradiated mice showed
similar DCF MFI after they were incubated with DCF (data not
shown). Furthermore, analysis of ROS production by DHE and
MitoSOX staining conﬁrmed that HSCs from irradiated mice pro-
duced increased levels of ROS compared to HSCs from control
unirradiated mice (Figs. 1C and 1D). In addition, our previous
studies showed that the increase in ROS production in irradiated
HSCs could be abrogated by preincubation of the cells with N-
acetylcysteine or treatment with MnTE-2-PyP [9]. Collectively,
these ﬁndings demonstrate that TBI can cause persistent oxidative
stress in HSCs. Metformin treatment markedly attenuated the
elevation of ROS production detected by DCFDA, DHE, and Mito-
SOX, demonstrating that metformin can effectively inhibit TBI-
induced chronic oxidative stress in HSCs. However, the effect of
metformin on ROS levels in irradiated HSCs was more pronounced
when ROS were analyzed by DCFDA and DHE than when detected
by MitoSOX, suggesting that the increased production of ROS in
irradiated HSCs might not be derived only from mitochondria but
also has a nonmitochondrial origin.
Metformin inhibits TBI-induced increases in DNA DSBs in HSCs
Because metformin can inhibit TBI-induced ROS production in
HSCs, next we examined whether metformin could reduce TBI-
induced persistent DNA damage in HSCs. This was accomplished
by ﬂow cytometric analysis of γH2AX staining in HSCs, because
γH2AX staining has been widely used as a surrogate for DNA DSBs.
As shown in Fig. 2, γH2AX staining in irradiated HSCs was
Fig. 1. Metformin inhibits the TBI-induced ROS increases in HSCs. The mice were treated with vehicle or metformin (250 mg/kg) by gavage 1 day before exposure to 4.0- Gy
TBI and then continuously for 7 days after TBI. A group of sham-irradiated mice was included as a control. The mice were euthanized 4 weeks after exposure to TBI to harvest
BM-MNCs. The ROS levels in HSCs were analyzed and presented as the means7SE from three independent experiments. apo0.05 vs control; bpo0.05 vs vehicleþTBI.
(A) Representative analysis of ROS levels in HSCs by ﬂow cytometry. (B) The levels of intracellular ROS in HSCs detected by the DCF MFI. (C) The levels of intracellular ROS in
HSCs detected by the DHE MFI. (D) The levels of intracellular ROS in mitochondria detected by the MitoSOX MFI.
Fig. 2. Metformin reduces the TBI-induced DSBs in HSCs. The mice were sham-irradiated as a control or irradiated and then treated with vehicle or metformin as described
in the text. BM-MNCs were isolated from the mice 4 weeks after TBI and then immunostained with antibodies against γH2AX to detect DSBs in HSCs. (A) Representative
analysis of γH2AX expression in HSCs by ﬂow cytometry. Black line depicts proﬁles of BM cells from control mice, red line depicts proﬁles of BM cells from vehicleþTBI mice,
and green line depicts proﬁles of BM cells from metforminþTBI mice. (B) The MFI7SE is shown. apo0.05 vs control; bpo0.001 vs vehicleþTBI.
G. Xu et al. / Free Radical Biology and Medicine 87 (2015) 15–2518signiﬁcantly increased even 4 weeks after TBI, conﬁrming our
previous ﬁnding that exposure of mice to TBI induces persistent
DNA damage in HSCs [9]. Treatment with metformin signiﬁcantly
reduced the increase in γH2AX staining in irradiated HSCs, in-
dicating that metformin treatment can inhibit TBI-induced DSBs in
HSCs.Metformin attenuates TBI-induced residual BM injury in part via
inhibition of HSC senescence but not apoptosis
Our recent studies have shown that the exposure of mice to TBI
induces persistent oxidative stress and DNA damage in HSCs,
which leads to the induction of HSC senescence and long-term BM
Fig. 3. Metformin attenuates the TBI-induced HSC reduction. The mice were sham-irradiated as a control or irradiated and then treated with vehicle or metformin as
described in the text. The frequency of HSCs in Lin BMCs was analyzed by ﬂow cytometry after the mice were euthanized 4 weeks after exposure to TBI. (A) Representative
results of the HSC ﬂow cytometric analysis. (B) The frequencies of HSCs in Lin BMCs are presented as the means7SE of three independent experiments. apo0.05 vs
control; bpo0.05 vs vehicleþTBI.
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because the irradiated mice receiving vehicle treatment exhibited
a substantial decrease in the frequency of HSCs (Fig. 3) and a
signiﬁcant reduction in 4-week CAFCs, which provides the mea-
surement of HSC clonogenic function (Fig. 4A). The long-term BM
suppression induced by TBI is probably attributable to the induc-
tion of HSC senescence as shown in our previous studies [4,5,9].Fig. 4. Metformin mitigates TBI-induced residual BM injury in part by inhibition of HS
treated with vehicle or metformin as described in the text. (A) The clonogenic functio
means7SE of the frequency of CAFCs per 105 BMCs from three independent assays. apo
sorted HSCs were analyzed by qRT-PCR and are expressed as the means7SE of fold cha
(C) HSC apoptosis was measured after the mice were euthanized 4 weeks after exposu
unchanged compared to the unirradiated group.This suggestion is supported by the ﬁndings that HSCs from ve-
hicle-treated TBI mice expressed elevated levels of p16 mRNA
(Fig. 4B), a widely used senescence biomarker and an important
mediator of cellular senescence induction [47,48]. However, after
treatment with metformin, the irradiated mice showed a sig-
niﬁcant recovery in the frequency of HSCs (Fig. 3) and remarkable
improvement in HSC clonogenic function (Fig. 4A), suggesting thatC senescence. The mice were sham-irradiated as a control or irradiated and then
n of HSCs in BMCs was measured by CAFC assay. The data are presented as the
0.05 vs control; bpo0.05 vs vehicleþTBI. (B) The levels of p16 mRNA expression in
nges compared to the control (n¼3). apo0.01 vs control; bpo0.01 vs vehicleþTBI.
re to TBI. The percentage of apoptotic cells in the irradiated group was relatively
Fig. 5. Metformin enhances long-term and multilineage engraftment of irradiated HSCs after BM transplantation. Donor cell engraftment was determined at 4 months in
lethally irradiated recipients after transplantation of BM-MNCs from the control or TBI mice treated with vehicle or metformin as described in the text through a competitive
repopulating assay. (A) Representative results of donor cell engraftment. The percentages of donor-derived (B) peripheral blood leukocytes (CD45.2þ cells), (C) T cells
(CD45.2þCD3þ cells), (D) B cells (CD45.2þB220þ cells), and (E) myeloid cells (CD45.2þCD11bþ and/or Gr-1þ cells granulocytes–monocytes–macrophages) are presented as
the means7SE (nine mice/group). apo0.01 vs control; bpo0.05 vs vehicleþTBI.
G. Xu et al. / Free Radical Biology and Medicine 87 (2015) 15–2520metformin treatment inhibited the IR-induced HSC senescence.
This suggestion is supported by the ﬁnding that metformin
treatment also reduced the IR-induced expression of p16 mRNA in
HSCs (Fig. 4B). In addition, no signiﬁcant increase in apoptosis was
detected in HSCs from mice that were exposed to TBI 4 weeks ago
compared to HSCs from unirradiated control mice (Fig. 4C). These
ﬁndings indicate that treatment with metformin can ameliorate
TBI-induced residual BM injury at least in part via the inhibition of
HSC senescence but not apoptosis.Metformin enhances long-term and multilineage engraftment of ir-
radiated HSCs after BM transplantation
Because long-term and multilineage engraftment is the only
gold standard for measuring HSC function [49], we performed a
competitive repopulation assay to validate whether the inhibition
of TBI-induced HSC senescence by metformin treatment can im-
prove HSC function. The mice that received donor cells from uni-
rradiated mice exhibited approximately 70% of the donor cell
G. Xu et al. / Free Radical Biology and Medicine 87 (2015) 15–25 21engraftment 4 months after transplantation (Fig. 5B), and 59.4% of
their T cells, 85.9% of their B cells, and 59.5% of their myeloid cells
were derived from the donor cells (Figs. 5C–5E). As shown in
Figs. 5B–5E, the mice that received donor cells from irradiated
mice with vehicle treatment showed a substantial decrease in
donor cell engraftment in all of the lineages. This decrease was
signiﬁcantly reduced when the irradiated donor mice were treated
with metformin (Figs. 5B–5E). These ﬁndings suggest that met-
formin treatment can preserve the function of HSCs after TBI, re-
sulting in an enhanced long-term and multilineage engraftment
after BM transplantation.
Metformin modulates the expression of NOX4 and antioxidant en-
zymes perturbed by TBI in HSCs
ROS are by-products of mitochondrial respiration, and thus,
mitochondria have been frequently considered to be the main
source of cellular-derived ROS, particularly after exposure to IR
[42–44]. However, an increasing body of evidence demonstrates
that cells can also produce ROS through the activation and/or in-
duction of NOXs [45,46]. Our previous studies showed that the
TBI-induced production of ROS in HSCs is probably attributable to
the upregulation of NOX4 [9]. However, the effects of TBI on the
expression of antioxidant enzymes in HSCs have not been studied.
SOD, CAT, and GPX1 are three major cellular antioxidant enzymes.
SOD converts superoxide radical into hydrogen peroxide (H2O2),
whereas GPX1 along with CAT converts H2O2 into water. To elu-
cidate the mechanisms of action through which metforminFig. 6. Metformin inhibits the TBI-induced NOX4 expression in HSCs. The mice were sham
described in the text. (A) The levels of NOX4 mRNA expression in sorted HSCs were anal
the control (n¼3). apo0.05 vs control; bpo0.001 vs vehicleþTBI. (B) Representative an
BM cells from control mice, red line depicts proﬁles of BM cells from vehicleþTBI mice, a
were isolated from the mice 4 weeks after TBI and then immunostained with antibodie
bpo0.001 vs vehicleþTBI.inhibits IR-induced chronic oxidative stress in HSCs after TBI, we
measured the expression of NOX4, SOD1, SOD2, CAT, and GPX1 in
HSCs from irradiated mice treated with vehicle or metformin. As
shown in Figs. 6 and 7A-D, TBI upregulated the expression of
NOX4 in HSCs but downregulated the expression of SOD1, SOD2,
CAT, and GPX1 mRNA in HSCs to variable degrees compared with
their respective controls. Metformin treatment not only reversed
the effects of IR on the expression of NOX4, SOD1, SOD2, CAT, and
GPX1 in HSCs but also signiﬁcantly inhibited the expression of
NOX4 in HSCs to a level that was even lower than that observed in
the control nonirradiated HSCs while increasing the expression of
SOD1, SOD2, CAT, and GPX1 mRNA (Figs. 6 and 7A-D). The mod-
ulation of antioxidant enzyme expression by TBI and metformin in
BM hematopoietic cells was also conﬁrmed by SOD, CAT, and GPX1
enzymatic assays shown in Fig. 7E-G. These results indicate that
TBI may increase ROS production in HSCs not only by upregulation
of NOX4 but also by downregulation of antioxidant enzymes,
whereas metformin inhibits TBI-induced chronic oxidative stress
in HSCs at least in part via downregulation of NOX4 expression
and upregulation of SOD, CAT, and GPX1 expression.Discussion
Recent clinical trials suggest that metformin, in addition to its
efﬁcacy in treating type 2 diabetes, may also have therapeutic
potential in other conditions, including diabetic nephropathy,
cardiovascular diseases, and polycystic ovary disease, and for-irradiated as a control or irradiated and then treated with vehicle or metformin as
yzed by qRT-PCR and are expressed as the means7SE of fold changes compared to
alysis of NOX4 expression in HSCs by ﬂow cytometry. Black line depicts proﬁles of
nd green line depicts proﬁles of BM cells from metforminþTBI mice. (C) BM-MNCs
s against NOX4 to detect MFI7SE in HSCs by ﬂow cytometry. apo0.05 vs control;
Fig. 7. Metformin increases the expression of SOD1, SOD2, CAT, and GPX1 mRNA in HSCs and the enzyme activity of SOD, CAT, and GPX1 in BM cells. The mice were sham-
irradiated as a control or irradiated and then treated with vehicle or metformin as described in the text. The mice were euthanized 4 weeks after exposure to TBI to harvest
BM-MNCs. HSCs were isolated from these cells by cell sorting and analyzed for the expression of SOD1, SOD2, CAT, and GPX1 mRNA by qRT-PCR. Enzyme activity of SOD, CAT,
and GPX1 in BM-MNCs was analyzed using a SOD assay kit, a CAT assay kit, and a cellular GPX1 assay kit, respectively. (A-D) Expression of SOD1, SOD2, CAT, and GPX1 mRNA
in HSCs. (E-G) Enzyme activity of SOD, CAT, and GPX1 in BM-MNCs. The levels of SOD1, SOD2, CAT, and GPX1 mRNA expression are expressed as the means7SE of fold
changes compared to the control (n¼3). apo0.05 vs control; bpo0.05 vs vehicleþTBI.
G. Xu et al. / Free Radical Biology and Medicine 87 (2015) 15–2522prevention or treatment of cancer [26,50,51]. However, the ther-
apeutic potential of metformin as a radiation protectant against IR-
induced long-term BM injury has not been investigated.
Our previous studies showed that exposure of mice to a sub-
lethal dose (6.0 or 6.5 Gy) of TBI can induce HSC senescence and
long-term BM suppression [9,40,41]. However, whether exposure
of mice to a lower dose (such as 4.0 Gy) of TBI can also induce HSCinjury has not been examined. The results from the present study
showed that exposure of mice to 4.0- Gy TBI also caused chronic
BM injury primarily by the induction of chronic oxidative stress in
HSCs, which led to persistent increases in DNA damage in HSCs
and induction of HSC senescence but not apoptosis. In addition, we
found that exposure to 4.0- Gy TBI upregulates NOX4 expression
and increases mitochondrial ROS production in HSCs, suggesting
G. Xu et al. / Free Radical Biology and Medicine 87 (2015) 15–25 23that increased production of ROS in irradiated HSCs may be at-
tributable to NOX4 and mitochondria. It has been shown that
metformin treatment can not only directly act on mitochondria to
inhibit respiration and ROS production [52] but also decrease the
production of ROS in podocytes and aortic endothelial cells
through reduction in NOX activity [53–55]. Our recent studies also
showed that resveratrol can ameliorate IR-induced long-term HSC
injury by decreasing ROS production in association with down-
regulation of NOX4 expression [41]. Therefore, we examined
whether metformin can inhibit IR-induced long-term BM injury in
part via downregulation of NOX4 and inhibition of mitochondrial
ROS production and senescence in HSCs. As shown in our study,
we found that treatment with metformin effectively inhibited TBI-
induced NOX4 expression and mitochondrial ROS production in
HSCs, which led to a signiﬁcant improvement in HSC clonogenic
function and long-term repopulating activity after transplantation.
Furthermore, we measured the expression of SOD1, SOD2, CAT,
and GPX1 mRNA in HSCs and the enzymatic activity of SOD, CAT,
and GPX1 in BM cells and found that TBI reduced their expression
and activity in hematopoietic cells. The reduction was attenuated
by metformin treatment. This ﬁnding suggests that metformin
may also inhibit TBI-induced chronic oxidative stress in HSCs in
part by modulating the expression of antioxidant enzymes.
Previous studies have found that oxidative stress can lead to
DNA damage such as DSBs [11,15]. DSBs can initiate DNA damage
response via sequential activation of ATM, Chk2, and p53 [56].
Activation of p53 induces p53 downstream targets, including the
cell cycle inhibitor p21Cip1/Waf1, to induce cell cycle arrest. It has
been suggested that the induction of DNA damage is also likely to
be responsible for the induction of hematopoietic genetic in-
stability by IR [57,58]. The induction of hematopoietic genetic in-
stability can lead to the development of leukemia in the victims of
nuclear events and cancer patients after radiation therapy. Pre-
vious studies have shown that metformin is a nongenotoxic and
noncytotoxic compound and may protect against genomic in-
stability induced by hyperglycemia [59]. In this study, we found
that metformin could reduce the increases in γH2AX expression in
HSCs after TBI, which conﬁrmed the effects of metformin on DNA
damage.
However, the mechanism by which metformin regulates NOX4
and SOD1, SOD2, CAT, and GPX1 expression has yet to be eluci-
dated. It has been well established that activation of AMPK is
closely related to the diversity function of metformin [16–18].
Activated AMPK switches cells from an anabolic to a catabolic
state, shutting down the ATP-consuming synthetic pathways and
restoring energy balance. This regulation involves the phosphor-
ylation by AMPK of key metabolic enzymes and transcription
factors that regulate gene expression [60]. As a result, glucose, li-
pid, and protein synthesis are inhibited, whereas fatty acid oxi-
dation and glucose uptake are stimulated. In addition, a growing
body of evidence from clinical studies and animal models suggests
that the primary function of metformin is to decrease hepatic
glucose production [61], mainly by inhibiting gluconeogenesis
[62,63]. Several mechanisms have been proposed to explain this
inhibitory action on hepatic gluconeogenesis, including changes in
enzyme activities [64–66] and a reduction in the hepatic uptake of
gluconeogenic substrates [67]. It remains to be determined whe-
ther the protection of metformin against IR-induced BM damage is
related to activation of AMPK and modulation of these metabolic
pathways.
Our studies indicate that metformin can be used as an efﬁca-
cious medical radiation countermeasure, particularly because
metformin is a safe drug that has been used extensively in the
clinic. The dose of metformin used in our study is safely achievable
in humans because the dose of 250 mg/kg/day of metformin in
mice is equivalent to 25 mg/kg/day in humans and a clinical studyhas shown that metformin does not cause any toxicity or side
effects in humans administered 1.0 to 2.5 g of metformin every day
[68]. An increasing body of evidence shows that metformin is
potent in cancer prevention and treatment, including breast can-
cer, prostate cancer, endometrial cancer, nasopharyngeal carcino-
ma, and esophageal squamous cell carcinoma [23–26,69]. More-
over, metformin can function as a radiosensitizer to increase the
radiosensitivity of cancer cells and signiﬁcantly enhance the
therapeutic efﬁcacy of radiation therapy for cancer [70–74].
Therefore, metformin not only has a radioprotection effect on HSCs
but also can act synergistically with IR in the treatment of cancer.Acknowledgments
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